These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19901323)

  • 1. Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.
    St-Germain JR; Taylor P; Tong J; Jin LL; Nikolic A; Stewart II; Ewing RM; Dharsee M; Li Z; Trudel S; Moran MF
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20127-32. PubMed ID: 19901323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of FGFR3 by PTPN1 and PTPN2.
    St-Germain JR; Taylor P; Zhang W; Li Z; Ketela T; Moffat J; Neel BG; Trudel S; Moran MF
    Proteomics; 2015 Jan; 15(2-3):419-33. PubMed ID: 25311528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
    Meyer AN; McAndrew CW; Donoghue DJ
    Cancer Res; 2008 Sep; 68(18):7362-70. PubMed ID: 18794123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of fibroblast growth factor receptor 3 and the adapter protein SH2-B. A role in STAT5 activation.
    Kong M; Wang CS; Donoghue DJ
    J Biol Chem; 2002 May; 277(18):15962-70. PubMed ID: 11827956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.
    Krejci P; Murakami S; Prochazkova J; Trantirek L; Chlebova K; Ouyang Z; Aklian A; Smutny J; Bryja V; Kozubik A; Wilcox WR
    J Biol Chem; 2010 Jul; 285(27):20644-53. PubMed ID: 20439987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation.
    Meyer AN; Gastwirt RF; Schlaepfer DD; Donoghue DJ
    J Biol Chem; 2004 Jul; 279(27):28450-7. PubMed ID: 15105428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
    Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
    J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.
    Salazar L; Kashiwada T; Krejci P; Meyer AN; Casale M; Hallowell M; Wilcox WR; Donoghue DJ; Thompson LM
    PLoS One; 2014; 9(1):e86470. PubMed ID: 24466111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer.
    Organ SL; Tong J; Taylor P; St-Germain JR; Navab R; Moran MF; Tsao MS
    J Proteome Res; 2011 Jul; 10(7):3200-11. PubMed ID: 21609022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
    Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
    J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
    Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
    Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
    Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
    Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
    Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
    Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
    Trudel S; Li ZH; Wei E; Wiesmann M; Chang H; Chen C; Reece D; Heise C; Stewart AK
    Blood; 2005 Apr; 105(7):2941-8. PubMed ID: 15598814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.
    Salazar L; Kashiwada T; Krejci P; Muchowski P; Donoghue D; Wilcox WR; Thompson LM
    Hum Mol Genet; 2009 Jun; 18(11):1951-61. PubMed ID: 19286672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein.
    Kanai M; Göke M; Tsunekawa S; Podolsky DK
    J Biol Chem; 1997 Mar; 272(10):6621-8. PubMed ID: 9045692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.
    Qian S; Somlo G; Zhou B; Zhu L; Mi S; Mo X; Cheung EM; Qiu W; Lin RJ; Rossi J; Holtz M; Chu P; Yen Y
    Oligonucleotides; 2005; 15(1):1-11. PubMed ID: 15788896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
    Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
    Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.
    Grand EK; Chase AJ; Heath C; Rahemtulla A; Cross NC
    Leukemia; 2004 May; 18(5):962-6. PubMed ID: 15029211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.
    Masih-Khan E; Trudel S; Heise C; Li Z; Paterson J; Nadeem V; Wei E; Roodman D; Claudio JO; Bergsagel PL; Stewart AK
    Blood; 2006 Nov; 108(10):3465-71. PubMed ID: 16849642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.